Upneeq
Upneeq
Upneeq

Upneeq

$ 258.75

${ formQuantity } @ ${ formatMoney(productOriginalPrice) }

${ computedProductOriginalPriceFormatted } ${ productPrice }
${ productVariantOptions[i] }: ${ optionSelections[i + 1] }

${ PdpError.description }

This item is currently only available for Preorder. Please read our Preorder Policy for more details.

Click Here For Authorization
Why do I need Authorization?
Before purchasing specific Face Reality products containing ingredients which are considered "Active", we require an acne consultation with one of our providers and an account through our online store. This acne consultation typically takes place via email correspondence and is used to educate customers on the best home-care for their skin. Once an acne consultation has been completed and a proper home care regimen determined, access to the active products may be approved. To request to be contacted by one of our skin care providers for an acne consultation, please complete the form below. If you have already received authorization and believe you are seeing this message in error, please contact us via email at support@dermspastore.com.
Request Authorization

Already Authorized? Log in to purchase

Description
How to use
Important information
Ingredient
Upneeq is the only FDA-approved prescription eyedrop for acquired ptosis (low-lying lids) that lifts your upper eyelids to open your eyes in as little as 5-15minutes.

Wash hands thoroughly before using Upneeq ®. Shake the vial well before inserting drops. 

 

Step 1: Cut open the foil wrapper and remove the single-use vial 

Step 2: Apply one drop of Upneeq ® in each affected eye as directed, once a day. 

 

Do not let the tip of the vial touch your eye or any other surface. Vials should not be re-used after opening and should be thrown away after applying drop(s). 

 

Upneeq ® should only be used as directed.

  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs. 
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens. 
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop. 
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop. 
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution),

 

 0.1% contains oxymetazoline hydrochloride, an alpha adrenoceptor agonist. UPNEEQ ® is an aseptically prepared, sterile, nonpreserved ophthalmic solution. Each mL of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution) 0.1% contains 1 mg of oxymetazoline hydrochloride, equivalent to 0.09 mg (0.09%) of oxymetazoline free base. The ophthalmic solution contains the following inactive ingredients: calcium chloride, hydrochloric acid (used to adjust pH to 5.8 to 6.8), hypromellose, magnesium chloride, potassium chloride, sodium acetate, sodium chloride, sodium citrate, and water for injection.

You May Also Like


Recently Viewed


Customer Reviews

No reviews yet
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)